Vimian Group AB (publ)

Stockholm Stock Exchange:VIMIAN.ST

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🍔 Meat

💊 Pharmaceuticals

💻 Telehealth

Location

Sweden

Market Cap

USD 2.19 B

Share Price

USD 4.18

Avg Daily Volume

446,769

Change (1 day)

0.95%

Change (1 year)

31.83%

Change (YTD)

16.18%

Vimian Group AB (publ) Operating Income Margin for the year ending December 31, 2024: 13.13%

Vimian Group AB (publ) Operating Income Margin is 13.13% for the year ending December 31, 2024, a 5.51% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Vimian Group AB (publ) Operating Income Margin for the year ending December 31, 2023 was 12.44%, a -11.08% change year over year.
Vimian Group AB (publ) Operating Income Margin for the year ending December 31, 2022 was 13.99%, a 12.31% change year over year.
Vimian Group AB (publ) Operating Income Margin for the year ending December 31, 2021 was 12.46%, a -77.06% change year over year.
Vimian Group AB (publ) Operating Income Margin for the year ending December 31, 2020 was 54.30%, a 954.70% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

Stockholm Stock Exchange: VIMIAN.ST

Vimian Group AB (publ)

CEO	Mr. Patrik Eriksson
IPO Date	June 18, 2021
Location	Sweden
Headquarters	Riddargatan 19
Employees	1,200
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🍔 Meat 💊 Pharmaceuticals 💻 Telehealth

Description

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.